Saturday 17 October 2026
Export CLVSQ’s income statement to Excel — free account
Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
| Sep '22 | Jun '22 | Mar '22 | Dec '21 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 4 | 3 |
+8 more TTM periods Free account |
| 78.31% | 91.63% | 98.57% | 120.90% | ||
| (58.94%) | (54.57%) | (51.66%) | (49.06%) | ||
ROIC |
0.00% | (73.03%) | (65.22%) | (71.85%) | |
Return on Tangible Assets |
39.31% | (997.42%) | (370.81%) | (333.04%) | |
Average Days of Receivables |
53.38 | 48.32 | 68.73 | 65.93 | |
Free Cash Flow per Share |
(1.22) | (1.26) | (1.40) | (1.70) | |
Free Cash Flow |
(175.84) | (181.30) | (192.92) | (196.37) | |
Capital Expenditures |
(0.27) | (0.27) | (0.26) | (0.31) | |
| Other line items | |||||
Cash ROIC |
(223.28%) | (48.04%) | (42.54%) | (40.64%) | |
Accounts Receivable Turnover |
5.88 | 6.56 | 5.91 | 5.57 | |
Accounts Payable Turnover |
1.76 | 1.64 | 1.80 | 1.44 | |
Inventory Turnover |
2.58 | 2.00 | 2.11 | 1.75 | |
Average Days of Payables |
178.95 | 231.46 | 211.02 | 256.72 | |
Days of Inventory on Hand |
112.75 | 126.41 | 137.05 | 128.68 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
113.73% | 118.85% | 121.45% | 125.44% | |
Selling, General and Administrative Expense of Revenue |
94.37% | 90.78% | 88.08% | 86.32% | |
Share Based Compensation of Revenue |
18.02% | 18.60% | 19.35% | 17.11% | |
Interest Coverage |
(2.78) | (3.05) | (3.10) | (3.31) | |
Operating CF/Net income |
0.70 | 0.69 | 0.75 | 0.74 | |
Depreciation/Fixed assets |
2.05 | 1.88 | 1.76 | 1.67 | |
Capex/Depreciation |
(0.03) | (0.03) | (0.02) | (0.03) | |
Revenue per Share |
0.92 | 0.97 | 1.05 | 1.29 | |
Operating CF per Share |
(1.21) | (1.26) | (1.39) | (1.70) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates